Bafna Pharmaceuticals Ltd. (NSE: BAFNAPH, BSE: 532989) is a Chennai, Tamil Nadu-based company in the Pharmaceuticals industry. With a market capitalisation of ₹1,091 Cr, it ranks #1,537 by market cap among the 6,137 Indian listed companies on FinBizNet, and #24 of 63 in Pharmaceuticals. At ₹442.95 (as of 25 Oct 2026), the share price is 7.7% below its 52-week high of ₹479.95 and 346.7% above its 52-week low of ₹99.16. The share price is up 195.6% over one year and up 86.0% over three months.
| Current Price | ₹442.95 |
|---|---|
| Market Cap | ₹1,091 Cr |
| NSE Symbol | BAFNAPH |
| BSE Code | 532989 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 100.3 |
| Return on Equity | 12.27% |
| Return on Assets | 4.02% |
| 52-Week Range | ₹99.16 – ₹479.95 |
| 1-Year Price Change | +195.6% |
| 3-Month Price Change | +86.0% |
| Beta (1Y) | -0.68 |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.bafnapharma.com |
| Revenue | ₹27 Cr |
|---|---|
| Net Profit | ₹0 Cr |
| Net Margin | 0.3% |
| EPS (Basic) | ₹0.03 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.
1. Pharmaceutical Formulations-This segment manufactures finished pharmaceutical formulations.
1. Manufacturing of Pharmaceuticals Formations,-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Bafna Pharmaceuticals Ltd. | ₹1,091 Cr | 100.3 | 12.27% | ₹27 Cr | +195.6% |
Listed by market capitalisation. Ratios are shown for context only.
Bafna Pharmaceuticals Ltd. is trading at ₹442.95, with a market capitalisation of ₹1,091 Cr.
Bafna Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Bafna Pharmaceuticals Ltd. has a P/E of 100.3 and a return on equity of 12.27%.
Bafna Pharmaceuticals Ltd. is listed on the NSE under the symbol BAFNAPH and on the BSE under the scrip code 532989.
Bafna Pharmaceuticals Ltd.'s share price is up 195.6% over one year and up 86.0% over three months. Its 52-week range is ₹99.16 to ₹479.95.
In Q1 FY27, Bafna Pharmaceuticals Ltd. reported revenue of ₹27 Cr and net profit of ₹0 Cr, with basic EPS of ₹0.03 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.